Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
- 1 June 2020
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 132, 112-121
Abstract
No abstract availableKeywords
Funding Information
- Memorial Sloan Kettering Cancer Center (CA0008748)
This publication has 28 references indexed in Scilit:
- The antineoplastic effect of low-molecular-weight heparins – a literature reviewContemporary Oncology, 2013
- Heparins modulate the IFN-γ-induced production of chemokines in human breast cancer cellsBreast Cancer Research and Treatment, 2012
- Low Molecular Weight Heparin Ablates Lung Cancer Cisplatin-Resistance by Inducing Proteasome-Mediated ABCG2 Protein DegradationPLOS ONE, 2012
- Concentration- and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitroCanadian Journal of Physiology and Pharmacology, 2011
- M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and MetastasisPLOS ONE, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Effect of Fraxiparine, a type of low molecular weight heparin, on the invasion and metastasis of lung adenocarcinoma A549 cellsOncology Letters, 2010
- The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber modelBritish Journal of Cancer, 2010
- Myeloid-Derived Suppressor Cells: Linking Inflammation and CancerThe Journal of Immunology, 2009
- Low‐molecular‐weight heparins and angiogenesisAPMIS, 2006